Sulfasalazine and Throat Pain: Immediate Action Required
Stop sulfasalazine immediately and obtain urgent complete blood count (CBC) with differential, as throat pain (sore throat) is a warning sign of potentially life-threatening agranulocytosis or serious blood dyscrasia 1.
Critical Warning Signs
The FDA drug label explicitly states that "the presence of clinical signs such as sore throat, fever, pallor, purpura, or jaundice may be indications of serious blood disorders or hepatotoxicity" 1. Throat pain in a patient on sulfasalazine is a red flag that cannot be ignored.
Immediate Management Algorithm
Discontinue sulfasalazine immediately - Do not wait for lab results 1
Obtain urgent laboratory testing:
- Complete blood count with differential
- Liver function tests
- Urinalysis with microscopic examination 1
Assess for additional warning signs:
Do not restart sulfasalazine until:
- Blood work confirms normal counts
- Alternative cause for throat pain is definitively established
- If agranulocytosis is confirmed, never rechallenge with sulfasalazine 1
Understanding the Risk
Sulfasalazine-induced agranulocytosis is rare but potentially fatal 2. The highest risk period is during the first two months of therapy 2, though it can occur at any time. Case reports document patients presenting with sore throat, fever, and odynophagia (painful swallowing) who were found to have white blood cell counts as low as 600/mm³ with 0% neutrophils 2.
Additional Serious Hypersensitivity Concerns
Throat pain may also herald Stevens-Johnson syndrome (SJS) or other severe hypersensitivity reactions. The FDA label warns that patients should be evaluated immediately if signs such as fever, lymphadenopathy, or mucosal lesions are present, even without visible rash 1. SJS can present with prodromal symptoms including sore throat and influenza-like symptoms before mucocutaneous lesions appear 3.
Clinical Pitfalls to Avoid
- Do not attribute throat pain to a simple viral infection without first ruling out drug-induced blood dyscrasia
- Do not continue sulfasalazine while "monitoring closely" - the drug must be stopped immediately 1
- Do not attempt desensitization if agranulocytosis or anaphylactoid reaction has occurred 1
Alternative Treatment Considerations
If the patient requires ongoing treatment for ulcerative colitis, the 2019 AGA guidelines recommend standard-dose mesalamine (2-3 grams/day) or diazo-bonded 5-ASA as preferred alternatives to sulfasalazine, specifically noting sulfasalazine's "higher rate of intolerance" 4. These alternatives do not carry the same hematologic toxicity risk profile.